Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 February 2010

Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial

Frank BoxbergerABCDEF, Heinz AlbrechtE, Peter C. KonturekE, Udo ReulbachCD, Gudrun MaennleinE, Thomas MeyerE, Werner HohenbergerE, Eckhart G. HahnE, Axel WeinABCDEF

Med Sci Monit 2010; 16(2): CR49-55 :: ID: 878350

Abstract

Background
In 2003 Wein et al. published data after a short median follow up (23 months). Here we report on the long-term results.
Material and Method
The patients (n=20) received a neoadjuvant treatment regimen comprising biweekly 85 mg/m2 oxaliplatin (L-OHP) (2h-infusion, d 1, 15, 29 qd 57) and 500 mg/m2 calcium folinic acid (FA) (1-2h-infusion, d 1, 8, 15, 22, 29, 36 qd 57) followed by 2600 mg/m2 5-Fluorouracil (5-FU) (24h-infusion, d 1, 8, 15, 22, 29, 36 qd 57). Two cycles of chemotherapy were administered, with a third being added when the treatment was well tolerated. Thereafter, curative resection of the liver metastases was attempted.
Results
After neoadjuvant therapy, imaging procedures revealed complete remission in 2 patients (10%) and partial remission in 18 patients (90%). Diarrhea (Common Toxicity Criteria toxicity grade 3) was observed in 6 patients (30%) as main symptom of toxicity, followed by vomiting in 3 patients (15%). Higher grade sensomotoric neuropathy did not present. The curative resectability rate (R0) was 80%. In 9 out of 18 patients (50%) undergoing surgical intervention minor postoperative complications occurred. No postoperative mortality was observed. Over a median follow up of 45,5 months the median survival of all patients is 3.0 years and the 5-year overall survival rate is 40%. The 5-year disease-free survival rate is 25%.
Conclusions
Neoadjuvant treatment with 5-FU combined with FA and L-OHP proved to be highly effective and well tolerated. Disease-free survival rates and median overall survival rates are promising.

Keywords: Organoplatinum Compounds - therapeutic use, Neoplasm Recurrence, Local - drug therapy, Neoadjuvant Therapy, Liver Neoplasms - surgery, Leucovorin - therapeutic use, Infusion Pumps, Implantable, Fluorouracil - therapeutic use, Drug Administration Schedule, Dose-Response Relationship, Drug, Colorectal Neoplasms - pathology, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Antineoplastic Agents - therapeutic use, Patient Compliance, Time Factors

Add Comment 0 Comments

Editorial

01 March 2025 : Editorial  

Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical Trials

Dinah V. Parums

DOI: 10.12659/MSM.948672

Med Sci Monit 2025; 31:e948672

0:00

In Press

Clinical Research  

Comparative Analysis of Laser Therapies for Striae Distensae: Fractional CO₂ vs Combined Q-Switch Nd:YAG

Med Sci Monit In Press; DOI: 10.12659/MSM.947464  

Database Analysis  

Utility of Central Venous Oxygen Saturation Gradient in Predicting Mortality in Dialysis with Catheter Access

Med Sci Monit In Press; DOI: 10.12659/MSM.947298  

Clinical Research  

Intraoperative Renal Near-Infrared Spectroscopy Monitoring as a Predictor of Renal Outcomes in Cardiac Surgery

Med Sci Monit In Press; DOI: 10.12659/MSM.947462  

Clinical Research  

Impact of Cholecalciferol Supplementation on Radiotherapy Outcomes in Advanced Cervical Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.945964  

Most Viewed Current Articles

17 Jan 2024 : Review article   7,110,480

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research   702,343

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Mar 2024 : Editorial   27,671

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...

DOI :10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

28 Jan 2024 : Review article   21,887

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future

DOI :10.12659/MSM.943912

Med Sci Monit 2024; 30:e943912

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750